details of the 10 patients in the open-label trial patientsymptomsresponseoutcome 1acute confusional...
DESCRIPTION
Details of the 10 patients in the open-label trial PatientSymptomsResponseOutcome 7Myelopathy, mood disorder, anxiety disorder Reduction of paresthesia, improvement of depressive state Remission for 9 m 8Psychosis, cognitive dysfunction Improvement of psychosis Remission for 6 m 9Acute confusional state, psychosis No signs or symptoms Remission for 6 m 10Acute confusional state, psychosis No signs or symptoms Remission for 24 m Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News; Nov 14, 2005]TRANSCRIPT
Details of the 10 patients in the open-label trial Patient Symptoms Response Outcome1 Acute
confusional state and psychosis
No signs or symptoms
Relapse of nephritis at 22 m; rituximab reapplied but failed
2 Acute confusional state
No signs or symptoms
Relapse of autoimmune hemolytic anemia at 18 m; rituximab reapplied and patient improved
3 Acute confusional state and seizures
No signs or symptoms
Relapse of NPSLE at 23 m; IV cyclophosphamide
Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News;
Nov 14, 2005] Rituximab for refractory neuropsychiatric SLE [Rheumawire > News;
Nov 14, 2005]
Details of the 10 patients in the open-label trial Patient Symptoms Response Outcome4 Severe headache Reduction of
headache Remission maintained for 24 m
5 Demyelinating syndrome
Reduction of paresthesia
Relapse of NPSLE at 7 m; IV cyclophosphamide
6 Mood disorder Improvement of depressive state
Remission for 7 m
Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News;
Nov 14, 2005] Rituximab for refractory neuropsychiatric SLE [Rheumawire > News;
Nov 14, 2005]
Details of the 10 patients in the open-label trial Patient Symptoms Response Outcome7 Myelopathy, mood
disorder, anxiety disorder
Reduction of paresthesia, improvement of depressive state
Remission for 9 m
8 Psychosis, cognitive dysfunction
Improvement of psychosis
Remission for 6 m
9 Acute confusional state, psychosis
No signs or symptoms
Remission for 6 m
10 Acute confusional state, psychosis
No signs or symptoms
Remission for 24 m
Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News;
Nov 14, 2005]